Key facts
- This page summarizes David D. Halbert's Form 4 filing for Caris Life Sciences, Inc. (CAI).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 18 May 2026, 16:22.
Key filing fact
Ownership activity is grounded in SEC Form 4 disclosures.
Shares, units, or other non-derivative securities reported in this filing.
Tax liability
No transaction description listed
Additional SEC filing notes
Footnote F1
Shares withheld for the payment of taxes on the vesting and settlement of RSUs.
Footnote F2
The Common Stock reported herein includes (i) 76,261,532 shares of Common Stock held by Caris Halbert, L.P., (ii) 8,528,805 shares of Common Stock held by ADAPT I Ltd., (iii) 8,414,427 shares of Common Stock held by Carisome I, L.P., (iv) 645,149 shares of Common Stock held by Caris Investment II Ltd, (v) 2,175,089 shares of Common Stock held by Caris Investment III Ltd, and (vi) 25,000,000 shares held by Halbert Family Capital, LLC. Caris Investment Management, LLC is the general partner of each of Caris Halbert, L.P., Caris Investment II Ltd., and Caris Investment III Ltd. Two family trusts are separately the general partner of ADAPT I Ltd. and the managing general partner of Carisome I, L.P., respectively. Caris Halbert, L.P. is the managing member of Halbert Family Capital, LLC.
Footnote F3
David Dean Halbert is the managing member of Caris Investment Management, LLC and the trustee of each of the two family trusts, and in such capacities, has voting and investment power with respect to the shares held by each of the foregoing entities. Mr. Halbert disclaims beneficial ownership except to the extent of his pecuniary interest therein.
SEC remarks
Founder, Chairman, and Chief Executive Officer